News
30 July, 2024 30 July, 2024 Recommendation of the President – Lynparza (olaparib)
read more30 July, 2024 The Transparency Council meeting 33/2024 on 5 August 2024
read more29 July, 2024 Recommendation of the President – Ilaris (canakinumab)
read more29 July, 2024 Recommendation of the President – Fintepla (fenfluramine)
read more29 July, 2024 Opinion of the President – HPP future without diabetes
read more26 July, 2024 Recommendation of the President – Cablivi (caplacizumab)
read more26 July, 2024 Recommendation of the President – Glycosade
read more26 July, 2024 Recommendation of the President – Keytruda (pembrolizumab)
read more26 July, 2024 Recommendation of the President – Cabomety (cabozantinib)
read more26 July, 2024 Recommendation of the President – Opdivo (nivolumab)
read more25 July, 2024 Opinion of the Transparency Council – Future without diabetes
read more25 July, 2024 Opinion of the Transparency Council – Program for prevention and early detection of eye defects in children aged 14 years residing in the municipality of Opalenica for 2024-2026
read more25 July, 2024 Opinion of the Transparency Council – Prevention and early detection of testicular cancer among men aged 20-39 years, residing in the Wielkopolska province for 2024-2025
read more25 July, 2024 Position of the Transparency Council – on the validity of the qualification of the service Gyroscopic Stereotactic Teleradiotherapy (TSZ) using the novel ZAP-X device
read more25 July, 2024 Position of the Transparency Council – Cablivi (caplacizumab)
read more25 July, 2024 Position of the Transparency Council – Ilaris (canakinumab)
read more25 July, 2024 Position of the Transparency Council – Tecentriq (atezolizumab)
read more25 July, 2024 Position of the Transparency Council – Fintepla (fenfluramine)
read more25 July, 2024 Position of the Transparency Council – Enhertu (trastuzumab deruxtecan)
read more25 July, 2024 Communication of the meeting of Transparency Council No. 31/2024 on 22 July 2024
read more24 July, 2024 Recommendation of the President – Agamree (vamorolone) in the indication of Becker muscular dystrophy
read more24 July, 2024 Recommendation of the President – Agamree (vamorolone) in the indication Duchenne muscular dystrophy
read more24 July, 2024 The Transparency Council meeting 32/2024 on 29 July 2024
read more